Gregory W. Albers

Gregory W. Albers

Auto-generated profile, based on publicly available information

Gregory W. Albers

Stanford Stroke Center, Stanford University, Palo Alto, CA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GAGregory W. Albers
Gregory W. Albers
MMMichael P. Marks
Michael P. Marks
SKStephanie Kemp
Stephanie Kemp
SCSoren Christensen
Soren Christensen
JTJenny P. Tsai
Jenny P. Tsai
MLMaarten G. Lansberg
Maarten G. Lansberg
Thrombectomy is currently recommended for eligible patients with stroke who are treated within 6 hours after the onset of symptoms. We conducted a multicenter, randomized, open-label trial, with blinded outcome assessment, of thrombectomy in patients 6 to 16 hours after they were last known to be well and who had remaining ischemic brain tissue that was not yet infarcted. Patients with proximal middle-cerebral-artery or internal-carotid-artery occlusion, an initial infarct size of less than 70 ml, and a ratio of the volume of ischemic tissue on perfusion imaging to infarct volume of 1.8 or more were randomly assigned to endovascular therapy (thrombectomy) plus standard medical therapy (endovascular-therapy group) or standard medical therapy alone (medical-therapy group). The primary outcome was the ordinal score on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability) at day 90. The trial was conducted at 38 U.S. centers and terminated early for efficacy after 182 patients had undergone randomization (92 to the endovascular-therapy group and 90 to the medical-therapy group). Endovascular therapy plus medical therapy, as compared with medical therapy alone, was associated with a favorable shift in the distribution of functional outcomes on the modified Rankin scale at 90 days (odds ratio, 2.77; P<0.001) and a higher percentage of patients who were functionally independent, defined as a score on the modified Rankin scale of 0 to 2 (45% vs. 17%, P<0.001). The 90-day mortality rate was 14% in the endovascular-therapy group and 26% in the medical-therapy group (P=0.05), and there was no significant between-group difference in the frequency of symptomatic intracranial hemorrhage (7% and 4%, respectively; P=0.75) or of serious adverse events (43% and 53%, respectively; P=0.18). Endovascular thrombectomy for ischemic stroke 6 to 16 hours after a patient was last known to be well plus standard medical therapy resulted in better functional outcomes than standard medical therapy alone among patients with proximal middle-cerebral-artery or internal-carotid-artery occlusion and a region of tissue that was ischemic but not yet infarcted. (Funded by the National Institute of Neurological Disorders and Stroke; DEFUSE 3 ClinicalTrials.gov number, NCT02586415.)

25 October 2006 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
GAGregory W. Albers
Gregory W. Albers
VTVincent N. Thijs
Vincent N. Thijs
LWLawrence Wechsler
Lawrence Wechsler
SKStephanie Kemp
Stephanie Kemp
GSGottfried Schlaug
Gottfried Schlaug
MMMichael P. Marks
Michael P. Marks

1 October 2012 in The Lancet Neurology
Verified
Journal Article
Closed access
MLMaarten G Lansberg
Maarten G Lansberg
MSMatus Straka
Matus Straka
SKStephanie Kemp
Stephanie Kemp
MMMichael Mlynash
Michael Mlynash
LWLawrence R Wechsler
Lawrence R Wechsler
GAGregory W Albers
Gregory W Albers

24 March 2017 in International Journal of Stroke
Verified
Journal Article
Closed access
PDF file
GAGregory W Albers
Gregory W Albers
MLMaarten G Lansberg
Maarten G Lansberg
SKStephanie Kemp
Stephanie Kemp
JTJenny P Tsai
Jenny P Tsai
PLPhil Lavori
Phil Lavori
MMMichael P Marks
Michael P Marks
Rationale: Early reperfusion in patients experiencing acute ischemic stroke is effective in patients with large vessel occlusion. No randomized data are available regarding the safety and efficacy of endovascular therapy beyond 6 h from symptom onset. Aim: The aim of the study is to demonstrate that, among patients with large vessel anterior circulation occlusion who have a favorable imaging profile on computed tomography perfusion or magnetic resonance imaging, endovascular therapy with a Food and Drug Administration 510 K-cleared mechanical thrombectomy device reduces the degree of disability three months post stroke. Design: The study is a prospective, randomized, multicenter, phase III, adaptive, blinded endpoint, controlled trial. A maximum of 476 patients will be randomized and treated between 6 and 16 h of symptom onset. Procedures: Patients undergo imaging with computed tomography perfusion or magnetic resonance diffusion/perfusion, and automated software (RAPID) determines if the Target Mismatch Profile is present. Patients who meet both clinical and imaging selection criteria are randomized 1:1 to endovascular therapy plus medical management or medical management alone. The individual endovascular therapist chooses the specific device (or devices) employed. Study outcomes: The primary endpoint is the distribution of scores on the modified Rankin Scale at day 90. The secondary endpoint is the proportion of patients with modified Rankin Scale 0–2 at day 90 (indicating functional independence). Analysis: Statistical analysis for the primary endpoint will be conducted using a normal approximation of the Wilcoxon–Mann–Whitney test (the generalized likelihood ratio test).

1 June 2008 in Chest
Verified
Journal Article
Closed access
GAGregory W. Albers
Gregory W. Albers
PAPierre Amarenco
Pierre Amarenco
JEJ. Donald Easton
J. Donald Easton
RSRalph L. Sacco
Ralph L. Sacco
PTPhilip Teal
Philip Teal

1 May 2011 in Stroke
Verified
Journal Article
Closed access
PDF file
MMMichael Mlynash
Michael Mlynash
MLMaarten G. Lansberg
Maarten G. Lansberg
DSDeidre A. De Silva
Deidre A. De Silva
JLJun Lee
Jun Lee
SCSoren Christensen
Soren Christensen
GAGregory W. Albers
Gregory W. Albers
Background and Purpose—: To refine the definition of the malignant magnetic resonance imaging profile in acute stroke patients using baseline diffusion-weighted magnetic resonance imaging (DWI) and perfusion-weighted magnetic resonance imaging (PWI) findings from the pooled DEFUSE/EPITHET database. Methods—: Patients presenting with acute stroke within 3 to 6 hours from symptom onset were treated with tissue plasminogen activator or placebo. Baseline and follow-up DWI and PWI images from both studies were reprocessed using the same software program. A receiver operating characteristic curve analysis was used to identify Tmax and DWI volumes that optimally predicted poor outcomes (modified Rankin Scale 5–6) at 90 days in patients who achieved reperfusion. Results—: Sixty-five patients achieved reperfusion and 46 did not reperfuse. Receiver operating characteristic analysis identified a PWI (Tmax>8 s) volume of >85 mL as the optimal definition of the malignant profile. Eighty-nine percent of malignant profile patients had poor outcome with reperfusion versus 39% of patients without reperfusion ( P =0.02). Parenchymal hematomas occurred more frequently in malignant profile patients who experienced reperfusion versus no reperfusion (67% versus 11%, P 8 s) of approximately 100 mL is appropriate for identifying these patients. Exclusion of malignant profile patients from reperfusion therapies may substantially improve the efficacy and safety of reperfusion therapies. Clinical Trial Registration Information—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00238537.